ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 186,18
-0,03%
Dow Jones
39 869,38
-0,10%
DAX
18 696,90
-0,15%
Brent Oil
83,475
0,32%
Bitcoin
66 370,83
1,73%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. PTC Therapeutics Inc (PTCT)

  7. PTC Therapeutics Inc (PTCT) Actualités

PTCT

PTC Therapeutics (PTCT)

PTC Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PTCT
DateHeureSourceTitreSymboleSociété
14/05/202413h30PR Newswire (US)PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™NASDAQ:PTCTPTC Therapeutics Inc
10/05/202423h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PTCTPTC Therapeutics Inc
07/05/202421h30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PTCTPTC Therapeutics Inc
02/05/202414h00PR Newswire (US)PTC Therapeutics to Participate at Upcoming Investor ConferencesNASDAQ:PTCTPTC Therapeutics Inc
25/04/202422h05PR Newswire (US)PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsNASDAQ:PTCTPTC Therapeutics Inc
23/04/202422h30PR Newswire (US)PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:PTCTPTC Therapeutics Inc
11/04/202414h00PR Newswire (US)PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial ResultsNASDAQ:PTCTPTC Therapeutics Inc
28/03/202413h30PR Newswire (US)PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMANASDAQ:PTCTPTC Therapeutics Inc
19/03/202412h30PR Newswire (US)PTC Therapeutics Provides Key Regulatory UpdatesNASDAQ:PTCTPTC Therapeutics Inc
29/02/202422h05PR Newswire (US)PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:PTCTPTC Therapeutics Inc
15/02/202414h00PR Newswire (US)PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:PTCTPTC Therapeutics Inc
14/02/202421h50Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:PTCTPTC Therapeutics Inc
14/02/202413h13Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PTCTPTC Therapeutics Inc
25/01/202422h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PTCTPTC Therapeutics Inc
25/01/202422h05PR Newswire (US)CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination ProcedureNASDAQ:PTCTPTC Therapeutics Inc
08/01/202415h26PR Newswire (US)PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:PTCTPTC Therapeutics Inc
03/01/202414h00PR Newswire (US)PTC Therapeutics to Participate at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:PTCTPTC Therapeutics Inc
05/12/202323h24Dow Jones NewsPTC Therapeutics Gives Updates on Translarna Regulatory ActivitiesNASDAQ:PTCTPTC Therapeutics Inc
05/12/202322h15PR Newswire (US)PTC Therapeutics Provides Updates on Translarna™ Regulatory ActivitiesNASDAQ:PTCTPTC Therapeutics Inc
07/11/202322h16Edgar (US Regulatory)Form POSASR - Post-effective Amendment to an automatic shelf registration statementNASDAQ:PTCTPTC Therapeutics Inc
26/10/202322h34Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PTCTPTC Therapeutics Inc
26/10/202322h05PR Newswire (US)PTC Therapeutics Provides Corporate Update and Reports Third Quarter Financial ResultsNASDAQ:PTCTPTC Therapeutics Inc
19/10/202314h00PR Newswire (US)PTC Therapeutics Announces Evrysdi® Royalty Agreement with Royalty Pharma for Up To $1.5 BillionNASDAQ:PTCTPTC Therapeutics Inc
16/10/202322h30PR Newswire (US)PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2023 Financial Results NASDAQ:PTCTPTC Therapeutics Inc
29/09/202313h29IH Market NewsFriday’s Wall Street Highlights: New Integrated, Nike, Tesla, Alphabet, and moreNASDAQ:PTCTPTC Therapeutics Inc
29/09/202302h12Dow Jones NewsStocks to Watch: Nike, Novo Integrated, PTC TherapeuticsNASDAQ:PTCTPTC Therapeutics Inc
28/09/202322h30PR Newswire (US)PTC Announces Further Strategic Prioritization and Associated Reduction in WorkforceNASDAQ:PTCTPTC Therapeutics Inc
15/09/202312h00PR Newswire (US)CHMP Delivers Opinion on Translarna™ for Conversion to Full AuthorizationNASDAQ:PTCTPTC Therapeutics Inc
07/09/202314h00PR Newswire (US)PTC Therapeutics' 2023 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient CommunityNASDAQ:PTCTPTC Therapeutics Inc
28/08/202314h00PR Newswire (US)PTC Therapeutics to Present Recent Data for Sepiapterin at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual SymposiumNASDAQ:PTCTPTC Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:PTCT

Dernières Valeurs Consultées

BIT
F35512
Vontobel Financial Produ...
USOTC
ACENY
Ascential (PK)
BIT
UC8HWW
Unicredit Bank
BIT
UV4LSW
UniCredit Bank
DBI
I2CL
IN XTK MSCI WLDSWAP DL I...
BIT
UC0HLE
Unicredit Bank
BIT
F37055
Vontobel Financial Produ...
BIT
UC1H05
Unicredit Bank
CSE
CGRO
Citation Growth
BIT
UB2RQX
UniCredit Bank
BIT
UR98ZG
UniCredit Bank
BIT
UC4AX7
Unicredit Bank
UNSW
SCATETH
Sad Cat Token
NASDAQ
MDWD
MediWound
BIT
UC24DW
Unicredit Bank
MRTX
CLMETH
Claymore
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés